Department of Nuclear Medicine, S. Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy.
Mol Imaging Biol. 2013 Apr;15(2):194-202. doi: 10.1007/s11307-012-0576-9.
TH-MYCN transgenic mice represent a valuable preclinical model of neuroblastoma. Current methods to study tumor progression in these mice are inaccurate or invasive, limiting the potential of this murine model. The aim of our study was to assess the potential of small animal positron emission tomography (SA-PET) to study neuroblastoma progression in TH-MYCN mice.
Serial SA-PET scans using the tracer 2-deoxy-2-[(18)F]fluoro-D-glucose ((18)F-FDG) have been performed in TH-MYCN mice. Image analysis of tumor progression has been compared with ex vivo evaluation of tumor volumes and histological features.
[(18)F]FDG-SA-PET allowed to detect early staged tumors in almost 100 % of TH-MYCN mice positive for disease. Image analysis of tumor evolution reflected the modifications of the tumor volume, histological features, and malignancy during disease progression. Image analysis of TH-MYCN mice undergoing chemotherapy treatment against neuroblastoma provided information on drug-induced alterations in tumor metabolic activity.
These data show for the first time that [(18)F]FDG-SA-PET is a useful tool to study neuroblastoma presence and progression in TH-MYCN transgenic mice.
TH-MYCN 转基因小鼠代表了一种有价值的神经母细胞瘤临床前模型。目前研究这些小鼠中肿瘤进展的方法不准确或具有侵入性，限制了该鼠模型的潜力。本研究旨在评估小动物正电子发射断层扫描（SA-PET）在研究 TH-MYCN 小鼠神经母细胞瘤进展中的潜力。
使用示踪剂 2-脱氧-2-[(18)F]氟-D-葡萄糖（(18)F-FDG）对 TH-MYCN 小鼠进行了连续的 SA-PET 扫描。肿瘤进展的图像分析与肿瘤体积和组织学特征的离体评估进行了比较。
[(18)F]FDG-SA-PET 几乎可以在 100%的疾病阳性 TH-MYCN 小鼠中检测到早期肿瘤。肿瘤演变的图像分析反映了肿瘤体积、组织学特征和疾病进展过程中的恶性程度的变化。对接受神经母细胞瘤化疗治疗的 TH-MYCN 小鼠进行的肿瘤代谢活性药物诱导改变的图像分析提供了信息。
这些数据首次表明，[(18)F]FDG-SA-PET 是研究 TH-MYCN 转基因小鼠中神经母细胞瘤存在和进展的有用工具。
